Loading...
•
Sep 30, 2023
TG Therapeutics Q3 2023 Earnings Report
TG Therapeutics reported strong Q3 2023 results driven by BRIUMVI sales and license revenue.
Key Takeaways
TG Therapeutics reported a strong third quarter with total net revenue of $165.8 million, including $25.1 million in BRIUMVI net sales in the U.S. and $140.0 million from license revenue. The company's cash position is $229.2 million, which is expected to fund planned operations into cash flow positivity.
Total net revenue reached $165.8 million, including $25.1 million from BRIUMVI sales in the U.S. and $140.0 million in license revenue.
Approximately 2,200 BRIUMVI prescriptions have been written since launch from 500+ healthcare providers.
Payor coverage is in place for approximately 95% of covered lives for BRIUMVI.
The company's cash position is $229.2 million.
Forward Guidance
TG Therapeutics anticipates that its cash, cash equivalents and investment securities as of September 30, 2023, combined with the projected revenues from BRIUMVI, will be sufficient to fund its planned operations into cash flow positivity based on the current operating plan.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...